![]() ![]() ![]() program at University of Rochester.Īnurima Sharma. program at Northwestern University.Īrvind Srivatsava. His other research interests involve leveraging CRISPRi/a unbiased screening to identify target genes that enhance β-cell survival upon treatment with environmental stressors known to inhibit transplantation efficacy or cell therapy functionality. Chandler’s current research focuses on understanding the importance of these cell types in the final cell therapy functionality. However, these cell products are not homogenous, containing populations of cells that co-differentiate into other islet cell types, such as α-cells, δ-cells and enterochromaffin cells. He joined the Millman Lab in the fall of 2021 with the intention to use his expertise in CRISPR-interference and CRISPR-activation techniques to further enhance the efficacy and mechanistic understanding of stem cell-derived β-cell populations as functional cures for Type 1 diabetes.ĭifferentiated β-cell populations have shown success in vitro and in vivo in functionally treating Type 1 diabetes. His doctoral research focused on vitamin A transport protein interactions both in delivery of vitamin A to an induced pluripotent stem cell model of the blood-brain barrier, and with beta-amyloid, the hallmark peptide implicated in Alzheimer’s disease. He moved north to earn his PhD in Chemical and Biological Engineering at the University of Wisconsin – Madison under the advisement of Professor Regina Murphy. He earned his bachelor’s degree in Chemical Engineering from the University of Missouri – Columbia (Mizzou) with minors in Biology and Mathematics. His other research interests include engineering kidney organoids, which can be combined with stem cell-derived ß-cells to potentially model diabetic kidney disease.Ĭhandler was born in Alabama, but raised in the St. Jeffrey Millman, into microfluidic systems to improve maturation and model the dynamic pathophysiology of diabetes. Matthew’s current research focuses on incorporating the functional, stem cell-derived ß-cells developed by his mentor, Dr. However, the integration of microfluidics and tissue engineering provides an avenue to develop dynamic in-vitro systems that model the function of human organs. Static cell culture systems and animal models are sometimes insufficient to recreate the complex, dynamic processes of human physiology and disease progression. In the summer of 2020, Matthew joined the Millman Lab with the goal of applying his skills toward engineering stem cell-derived ß-cells. Additionally, Matthew co-founded a Bio-Vitro, a startup aimed at commercializing the organ-on-chip technology he helped developed. His work developing a glomerulus-on-chip was funded by a National Research Service Award Predoctoral Fellowship (F31) from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases. His doctoral research focused on combining microfluidics and tissue engineering to develop organ-on-chip devices with the goal of developing new models of human organ function to improve methods for studying diseases. He competed the BS/MS program in Biomedical Engineering at the University of Miami in 2015 and then completed his PhD under the mentorship of Dr. Matthew was born and raised in South Florida. His other research interests include encapsulation and immunoprotection strategies for transplantation of these cells. Nathaniel’s current research focuses on further improving the maturation and function of these β-cells through a tissue engineering approach, such as incorporating cues from the native extracellular matrix that surrounds β-cells in vivo. Jeffrey Millman, previously developed with colleagues a six stage protocol for differentiating human pluripotent stem cells into functional β-cells using a step-wise combination of soluble factors. Transplantation of mature β-cells offers a potential cure for this disease, but a reliable source of functional β-cells is vital to this approach. Type 1 diabetes results from the loss of insulin-producing β-cells within the pancreas. He joined the Millman Lab in the fall of 2016 with the hopes of using these skills to help improve the differentiation of stem cell-derived β-cells and assist in the tissue engineering of pancreatic islets. His doctoral research focused on the importance of insoluble cues from the cellular microenvironment on particular cell behaviors, such as human mesenchymal stem cell differentiation. He then completed his PhD in Biomedical Engineering at The Ohio State University in 2016 under the guidance of Dr. He moved to Ohio to continue his education, earning his bachelor’s degree in Chemical Engineering from the University of Dayton with minors in Biology and Bioengineering.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |